Company intelligence / Profile preview

Mango DAT

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Mango Therapeutics is an early-stage biotechnology company focused on developing next-generation small molecule modulators of the dopamine transporter (DAT). The company aims to address limitations of current stimulant medications used for neuropsychiatric conditions by creating therapies with improved safety profiles and reduced potential for abuse. Their lead programs target indications such as attention deficit hyperactivity disorder (ADHD) and binge eating disorder. By leveraging structural biology and advanced medicinal chemistry, Mango Therapeutics seeks to optimize the kinetics and selectivity of DAT inhibition.

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Mango DAT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mango DAT.

Explore the full profile